Phase 2Data readout

Relacorilant + Nab-Paclitaxel & Bevacizumab (GR Antagonist)

Platinum-Sensitive Ovarian Cancer

CORTCorcept Therapeutics

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: Relacorilant + Nab-Paclitaxel & Bevacizumab (GR Antagonist)
Development stage: Phase 2
Event type: Data readout
Indication: Platinum-Sensitive Ovarian Cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Relacorilant + Nab-Paclitaxel & Bevacizumab (GR Antagonist) in Platinum-Sensitive Ovarian Cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

07/29/26:- BELLA Part B enrollment continues. Results remain expected by Q4 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

Relacorilant + Nab-Paclitaxel & Bevacizumab (GR Antagonist)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

Lifyorli (relacorilant) + Nab-paclitaxel

Relacorilant

Miricorilant

Relacorilant + Nab-Paclitaxel & Gemcitabine (GR Antagonist)